Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Free Cash Flow (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Free Cash Flow for 6 consecutive years, with -$17.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow rose 21.54% to -$17.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$67.9 million, a 62.27% increase, with the full-year FY2025 number at -$67.9 million, up 62.27% from a year prior.
  • Free Cash Flow was -$17.2 million for Q4 2025 at Lexicon Pharmaceuticals, up from -$23.8 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $17.0 million in Q2 2025 to a low of -$55.1 million in Q1 2024.
  • A 3-year average of -$34.2 million and a median of -$40.0 million in 2023 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: tumbled 73.03% in 2024, then soared 134.83% in 2025.
  • Lexicon Pharmaceuticals' Free Cash Flow stood at -$50.5 million in 2023, then soared by 56.55% to -$22.0 million in 2024, then rose by 21.54% to -$17.2 million in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Free Cash Flow are -$17.2 million (Q4 2025), -$23.8 million (Q3 2025), and $17.0 million (Q2 2025).